BioSpace News Archive

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT),

Pairing with market leader marks Massage Envy’s deeper move into high-end skin care services

Compelling preclinical data for its Cdc7 inhibitor, SRA141, indicate a potentially novel and distinct mechanism of action

Aimmune Therapeutics, Inc. announced that Jayson Dallas, M.D., President and Chief Executive Officer, will present at the Needham & Company 18th Annual Healthcare Conference on Wednesday, April 10, 2019, at 8:00 a.m. Eastern Time in New York City.

IMV Inc. announced that preclinical research presented at the American Association for Cancer Research Annual Meeting 2019 demonstrated how the mechanism of action of IMV’s proprietary DPX technology can enhance a broad spectrum of immune cell infiltration into tumors, which included T cells, Natural Killer cells, and macrophages.

Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumors, today announced that Drew Fromkin, President and Chief Executive Officer, will present at Needham & Company’s 18th Annual Healthcare Conference

The Ontario Bioscience Innovation Organization (OBIO®) is proud to announce its 2019 Capital Access Advisory Program (CAAP®) and the high-potential health science companies in this year’s program.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will give a company presentation on Monday, April 8, 2019 at 2:10 p.m. BST

EvoNexus, Southern California’s leading startup incubator with locations in San Diego and Irvine, in partnership with EMD Performance Materials, the North America high-tech materials business of Merck KGaA, Darmstadt, Germany, today announced it has launched an open application round in search of early stage companies with emerging technologies and use cases relevant to EMD Performance Materials’ core business

Glioblastoma is the most aggressive type of primary brain cancer, one with a prognosis of 11-15 months with standard treatment. Results from a phase 1b clinical trial of a new experimental glioblastoma vaccine developed by Jefferson Health and Imvax, show the treatment was tolerated well by patients, slowed tumor recurrence, and prolonged patient survival.